The MVA vaccine primes/expands IE2-specific CTLs that recognize IE2 peptides on MHC I of CMV-infected cells and kill them via perforin/granzyme-mediated cytolysis (with CD4+ T-cell help); the vaccine itself is not directly cytotoxic.